Author(s): DARIUSZ BORUCZKOWSKI1, KATARZYNA PAWELEC1,2, MACIEJ BORUCZKOWSKI3,DOMINIKA GÅADYSZ1
Cord blood-derived hematopoietic stem cells have been used in the clinic for more than 25years, and right now another source of neonatal stem cells, cord tissue, comes into spotlight.A part of umbilical cord, called Wharton’s jelly, is an abundant source of mesenchymal stemcells which hold promise for regenerative medicine. Their high proliferation and differentia-tion capabilities as well non or weakly immunogenic characteristics makes them good can-didates even for an allogenic use. Allogeneic mesenchymal stem cells have been widely usedin treating Graft-versus-Host Disease. Worldwide they have been already used in therapy ofvarious gynecological (i.a. urinary and anal incontinence) and neurological disorders (i.a.cerebral palsy) with preliminary promising results. First neurological patients currently under-go stem cell treatment as experimental therapy after individual bioethical committee approval.